---
theme: academic
layout: cover
class: text-white
coverAuthor: beau hilton 
coverAuthorUrl: https://www.beauhilton.com
coverDate: "2023-03-31"
coverBackgroundUrl: ./images/clocks.jpg
themeConfig:
  paginationX: r
  paginationY: t
  paginationPagesDisabled: [1]
title: Lower-Risk MDS
info: |
  # Lower-Risk MDS
  Case Conference 2023-03-31, [Beau Hilton](https://www.beauhilton.com)

---

# Lower-Risk MDS

---

# Case presentation

<br>

81M w CKD (b/l Cr 1.8), HFpEF (admitted 2x last year), AF (on apixaban), p/w hgb 10.1, MCV 99.

<v-clicks>

Feels fine overall, some DoE that is longstanding, doing well since last admission and diuresis.

No frequent infections. 

Doesn't have dentures, no OTC supps.

</v-clicks>

---

# Case presentation

## Labs

<v-clicks>

- hgb 10.1, MCV 99
- plt 132
- WBC 5.3, normal diff

- folate, B12 replete

- TSAT 19%

</v-clicks>

---

# Case presentation

<v-clicks>

Given 1g IV iron, seen back in 10wks, BMBx scheduled prophylactically

hgb 9.6, MCV 97

other counts unchanged

</v-clicks>

---

# Case presentation

## BMBx

<v-clicks>

- something
- something else

</v-clicks>

---

# Questions

- How common is MDS?
- What do people present with?
- How do we risk-stratify MDS?
- What are the relative incidences of the risk strata?
- When do we intervene in lower-risk disease?
- What tools do we have?
- How do we sequence therapies?
- Can we impact prognosis?

---


# Epidemiology

<v-clicks>

- yearly incidence: 4/100,000<sup>1</sup>
- incidence increases with age:<sup>2</sup>
  - <40yo: 0.1/100,000
  - \>65yo: 25/100,000
  - 70-79yo: 30/100,000
  - \>80yo: 60/100,000
  - underreported: yearly incidence >65yo may be as high as 75/100,000<sup>3</sup>
- median age of dx: 70-75
- male predominance
  - 5.4/100,000 vs 2.9/100,000 in women
  - del(5q) more common in women (7:3)
- 75% are LR-MDS

</v-clicks>



<Footnotes separator class="footnote">
  <Footnote :number=1><a href="https://beauhilton.com" rel="noreferrer" target="_blank">Sekeres</a></Footnote>
  <Footnote :number=2><a href="https://beauhilton.com" rel="noreferrer" target="_blank">Toprak</a></Footnote>
  <Footnote :number=3><a href="https://beauhilton.com" rel="noreferrer" target="_blank">de Witte 2020</a></Footnote>
</Footnotes>

---

# S/sx prevalence (%)<sup>1</sup>

<table class="tg">
<tbody>

<tr>
 <td> Fatigue </td>
 <td> 55 </td>
</tr>

<tr>
 <td> Hgb &lt;10 g/dL </td>
 <td> 52 </td>
</tr>

<tr>
 <td> Plt &lt;100 x 10<sup>9</sup>/L </td>
 <td> 40 </td>
</tr>

<tr>
 <td> ANC &lt;800 x 10<sup>9</sup>/L </td>
 <td> 18 </td>
</tr>

<tr>
 <td> Fever/infection </td>
 <td> 15 </td>
</tr>

<tr>
 <td> Bleeding </td>
 <td> 8 </td>
</tr>


</tbody>
</table>

<Footnotes separator>
  <Footnote :number=1><a href="https://beauhilton.com" rel="noreferrer" target="_blank">Sekeres</a></Footnote>
</Footnotes>

---

# Diagnosis

- &ge;1 cytopenias
  - hgb &lt;10, ANC &lt;1800, plt &lt;100k
- &ge;10% dysplastic cells in &ge;1 lineage
- &lt;20% blasts
- presence of certain cytogenetic/molecular findings
  - _absence_ of AML-defining (cyto)genetics (e.g. t(8;21), CBFB-MYH11)


---
layout: figure
figureUrl: ./images/ipssr-surv-aml.png
---

# Risk stratification


---

# Risk stratification (IPSS)

<table>
<tbody> 
  <tr> 
    <td rowspan="2">Variable</td> 
    <td colspan="5">Score</td> 
  </tr> 
  <tr> 
    <td>0</td> 
    <td>0.5</td> 
    <td>1</td> 
    <td>1.5</td> 
    <td>2</td> 
  </tr> 
  <tr> 
    <td>Bone marrow blasts (percent)</td> 
    <td>&lt;5</td> 
    <td>5-10</td> 
    <td>-</td> 
    <td>11-20</td> 
    <td>21-30</td> 
  </tr> 
  <tr> 
    <td>Karyotype</td> 
    <td>Good</td> 
    <td>Intermediate</td> 
    <td>Poor</td> 
    <td>-</td> 
    <td>-</td> 
  </tr> 
  <tr> 
    <td>Cytopenias</td> 
    <td>0-1</td> 
    <td>2-3</td> 
    <td>-</td> 
    <td>-</td> 
    <td>-</td> 
  </tr> 
</tbody>
</table>

<br>

- Karyotype stratification:
  - Good: Normal, -Y, del(5q), del(20q)
  - Intermediate: not good nor poor
  - Poor: &ge;3 abnl, chromosome 7 abnl 


---

# Risk stratification (IPSS)

<table>
<tbody>
  <tr> 
    <td>Risk group</td> 
    <td>IPSS score</td> 
  </tr> 
  <tr> 
    <td>Low</td> 
    <td>0</td> 
  </tr> 
  <tr> 
    <td>Intermediate-1</td> 
    <td>0.5 to 1</td> 
  </tr> 
  <tr> 
    <td>Intermediate-2</td> 
    <td>1.5 to 2</td> 
  </tr> 
  <tr> 
    <td>High</td> 
    <td>2.5 to 3.5</td> 
  </tr> 
</tbody>
</table>

---

# Risk stratification (IPSS-R)

<table>
<colgroup span="8" width="12%"></colgroup> 
<tbody> 
  <tr> 
    <td rowspan="2"></td> 
    <td colspan="7"></td> 
  </tr> 
  <tr> 
    <td>0</td> 
    <td>0.5</td> 
    <td>1.0</td> 
    <td>1.5</td> 
    <td>2.0</td> 
    <td>3.0</td> 
    <td>4.0</td> 
  </tr> 
  <tr> 
    <td>blast %</td> 
    <td>≤2 </td> 
    <td>&nbsp;</td> 
    <td>&gt;2 - &lt;5 </td> 
    <td>&nbsp;</td> 
    <td>5 - 10 </td> 
    <td>&gt;10 </td> 
    <td>&nbsp;</td> 
  </tr> 
  <tr> 
    <td>hgb</td> 
    <td>≥10</td> 
    <td>&nbsp;</td> 
    <td>8 - &lt;10</td> 
    <td>&lt;8</td> 
    <td>&nbsp;</td> 
    <td>&nbsp;</td> 
    <td>&nbsp;</td> 
  </tr> 
  <tr> 
    <td>plt</td> 
    <td>≥100</td> 
    <td>50 - 100</td> 
    <td>&lt;50</td> 
    <td>&nbsp;</td> 
    <td>&nbsp;</td> 
    <td>&nbsp;</td> 
    <td>&nbsp;</td> 
  </tr> 
  <tr> 
    <td>ANC</td> 
    <td>≥0.8</td> 
    <td>&lt;0.8</td> 
    <td>&nbsp;</td> 
    <td>&nbsp;</td> 
    <td>&nbsp;</td> 
    <td>&nbsp;</td> 
    <td>&nbsp;</td> 
  </tr> 
  <tr> 
  <td>cytogenetics</td> 
    <td>very good
    <p class="text-xs"> -Y, del(11q)</p>
    </td> 
    <td>&nbsp;</td> 
    <td>good
    <p class="text-xs"> normal, del(12p), del(20q), del(5q), <mark>double w del(5q)</mark></p>
    </td> 
    <td>&nbsp;</td> 
    <td>intermediate
    <p class="text-xs"> single NOS, del(7q), +8, +19, i(17q), <mark>double w/o del(5q) or -7/del(7q)</mark></p>
    </td> 
    <td>poor
    <p class="text-xs"> -7, <mark>double w -7/del(7q)</mark>, inv(3)/t(3q)/del(3q), 3 abnl</p>
    </td> 
    <td>very poor
    <p class="text-xs">&gt;3 abnl</p>
    </td> 
  </tr> 
</tbody>
</table>

---

# Risk stratification (IPSS-R)

<table>
<tbody>
<tr> 
<td colspan="2">Risk group</td> 
<td colspan="2">IPSS-R score</td> 
</tr> 
<tr> 
<td colspan="2">very low</td> 
<td colspan="2">≤1.5</td> 
</tr> 
<tr> 
<td colspan="2">low</td> 
<td colspan="2">&gt;1.5 to 3.0</td> 
</tr> 
<tr> 
<td colspan="2">intermediate</td> 
<td colspan="2">&gt;3 to 4.5</td> 
</tr> 
<tr> 
<td colspan="2">high</td> 
<td colspan="2">&gt;4.5 to 6</td> 
</tr> 
<tr> 
<td colspan="2">very high</td> 
<td colspan="2">&gt;6</td> 
</tr> 
</tbody>
</table>

---
layout: figure
figureUrl: ./images/ipss-x.jpeg
figureFootnoteNumber: 1
figureCaption: Newer risk stratification strategies attempt to address shortcomings with prior models (e.g. new mutations of significance, significant heterogeneity within risk groups). Because they are complex, they are not in widespread use outside of research settings.
---

# Risk stratification (IPSS-many)

<Footnotes separator class="footnote">
  <Footnote :number=1><a href="https://doi.org/10.1182/blood-2022-159939">Baer et al</a></Footnote>
</Footnotes>

---

# Management

## Goals of management
  
No interventions have been shown conclusively to improve OS in LR-MDS.<sup>1</sup>

<v-clicks>

- reduce sx
- reduce tfx dependence
- minimize morbidity
- balance tox of tx vs tox of dz

</v-clicks>

<Footnotes separator class="footnote">
  <Footnote :number=1>there is now a suggestion that early EPO may improve OS (Garelius 2022, abstract at the EHA Annual Congress)</Footnote>
</Footnotes>

---

# Management - anemia


## EPO

<v-clicks>

- relatively high dose, e.g. 60,000u EPO q7d, 500 μg darbepoetin alfa q21d
- meta-analysis: ~40% response rate overall (hgb up 1-1.5g, reduction in tfx)
- 2017 RCT: 15% RR at 24wk (0% in placebo)
  - Open-label 48wk f/u: 35% RR
- response rate is higher if lower baseline EPO (e.g.<200 IU/L)
  - if high tfx dependence (&ge;1 tfx/14d) and EPO >200, RR <10%
- mean duration of response: 8-23mo
- fever in 10%

</v-clicks>

---

# Management - anemia

## luspatercept

<v-clicks>


- TGF-b superfamily, promotes late-stage erythropoeisis
- MDS-RS (usu SF3B1-mutant)
- tfx independence in ~40% (~10% in placebo)
- median duration of response ~30wks
- diarrhea, nausea, back pain, dizziness in 20%

</v-clicks>

## lenalidomide

<v-clicks>

- del(5q) (sometimes non-del(5q) if used in combo w epoeitin alfa)
- 21/28d cycles
- 2011 RCT: tfx independence in 40-60%
- median duration of response >2y
- G3-4 neutropenia 70%, thrombocytopenia in ~33%

</v-clicks>

---

# Management - anemia - new stuff

## imetelstat

<v-clicks>

- telomerase inhibitor
- IV, 2h infusion q4wks
- "IMerge" trial (phase 2 complete, phase 3 finished recruiting)
- R/R tfx burden (&ge;4 pRBC/8wks)
- primary endpoint: transfusion independence &ge;8wk
- 37% reached primary endpoint
- 42% >8wks, 32% >24wks, 29% >52wks
- possibly disease-modifying (clonal burden decreased in some)

</v-clicks>

---

# Management - anemia - new stuff


## roxadustat

<v-clicks>

  - HIF inhibitor (approved in China for CKD, not approved in US d/t c/f thrombosis, CV events)
  - oral, 3x/wk
  - phase 3, LR-MDS, <5% blasts, low tfx burden
  - ~50% reduction in tfx
  - EPO level doesn't seem to matter, but sample size is small

</v-clicks>

## H3B-8800

<v-clicks>

  - spliceosome modulator (e.g. SF3B1, SRSF2, U2AF1)
  - oral
  - 42 pts w HR or LR-MDS, 88% w spliceosome mutations
  - 14% had reduced pRBC or plt tfx dependence

</v-clicks>



---

# Management - thrombocytopenia

## romiplostim<sup>1</sup>

<v-clicks>

- plt <20k: 1250 vs 1800 plt tfx per 100 pt-years
- plt >20k: 80 vs 225 bleeding events per 100 pt-years

</v-clicks>

## eltrombopag<sup>1</sup>

<v-clicks>

- baseline plt <30k
- improved plt count in 50% (3% in placebo)

</v-clicks>


<Footnotes separator class="footnote">
  <Footnote :number=1>TPO possibly yield higher risk of AML transformation, particularly in MDS-EB, but longer f/u studies failed to show an association (e.g. Kantarjian 2018)</Footnote>
</Footnotes>


---

# Management - multipenia/neutropenia

<v-clicks>

- HMA
  - may be able to use 3d cycles, rather than 5/7
  - 29% CR or PR (12% w best supportive care)
  - oral HMA are approved for IR-MDS and HR-MDS, phase 1/2 studies for LR-MDS are underway
- ATG

</v-clicks>

---

# Management 

## MDS-hypoplastic

- LR-MDS w <25% cellularity appears to somewhat overlap w aplastic anemia
- so -> ATG, cyclosporine, etc.


---
layout: index
indexEntries:
  - { title: "HemOnc.org entry", uri: "https://hemonc.org" }
  - { title: "NCCN Guidelines", uri: "https://www.nccn.org/professionals/physician_gls" }
  - { title: "PathologyOutline", uri: "https://www.pathologyoutlines.com" }
  - { title: "", uri: "" }
  - { title: "", uri: "" }
  - { title: "", uri: "" }
  - { title: "", uri: "" }
  - { title: "", uri: "" }
indexRedirectType: external
---

# Resources

---

# Bibliography

Use HTML export from Zotero. 
It's great. 
Looks kinda like the following 
(note I changed the text size with `text-sm` from WindiCSS.)

<div class="csl-bib-body text-sm" style="line-height: 1.35; margin-left: 2em; text-indent:-2em;">
  <div class="csl-entry">Al Subhi, Abdul Rahman, Veronica Boyle, and Marianne S. Elston. “Systematic Review: Incidence of Pheochromocytoma and Paraganglioma Over 70 Years.” <i>Journal of the Endocrine Society</i> 6, no. 9 (September 1, 2022): bvac105. <a href="https://doi.org/10.1210/jendso/bvac105">https://doi.org/10.1210/jendso/bvac105</a>.</div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_id=info%3Adoi%2F10.1210%2Fjendso%2Fbvac105&amp;rft_id=info%3Apmid%2F35919261&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Systematic%20Review%3A%20Incidence%20of%20Pheochromocytoma%20and%20Paraganglioma%20Over%2070%20Years&amp;rft.jtitle=Journal%20of%20the%20Endocrine%20Society&amp;rft.stitle=J%20Endocr%20Soc&amp;rft.volume=6&amp;rft.issue=9&amp;rft.aufirst=Abdul%20Rahman&amp;rft.aulast=Al%20Subhi&amp;rft.au=Abdul%20Rahman%20Al%20Subhi&amp;rft.au=Veronica%20Boyle&amp;rft.au=Marianne%20S.%20Elston&amp;rft.date=2022-09-01&amp;rft.pages=bvac105&amp;rft.issn=2472-1972&amp;rft.language=eng"></span>
</div>

---
